From Complete Catalogs to "Actionable" Shortlists: Integrative Analysis of Next-generation Sequencing Data in Cancer Research



May 28, 2013

  • Share
  • Next-generation sequencing has become a revolutionary tool for cancer research. However, there is still a big gap between complete catalogues of genomic alternations identified from NGS studies and “actionable” shortlists for further functional investigation. Using my two recent studies (RNA-seq in gastric cancer and exome-seq in endometrial cancer), I will discuss how to identify “driver” genes underlying the tumorigenesis. In the first study, we performed a comprehensive analysis on the whole-transcriptome of gastric cancer, and developed a multilayer and integrative analytic framework for identifying potential therapeutic targets from RNA-seq data (Kim et al., Cancer Research 2012). In the second study, we developed an integrated systems-biology approach to identifying driver somatic mutations from whole-exome sequencing data, which combines bioinformatics prioritization, a high-throughput approach to generating mutants and high-through cell viability assays (Liang et al., Genome Research 2012).

    Drug DiscoveryGenomicsInformatics

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.